• Initiation of Phase 1 trial of RC220 in combination with doxorubicin with first patient treatment expected in Q2 CY2025
• Ethics approval received for trial initiation at Gosford and Wyong Hospitals
• Cash and cash equivalents of $17.12m as of 31 March 2025

Race Oncology Ltd (ASX: RAC) has released its Q3 FY2025 quarterly report for the period ended 31 March 2025. The company made significant progress towards the first patient treatment in its Phase 1 trial of RC220 in combination with doxorubicin in patients with advanced solid tumours, receiving all necessary ethics and regulatory approvals. Screening of patients has begun, and the treatment of the first patient with RC220 is expected in the current quarter. Race also received ethics approval to begin the trial at the Gosford and Wyong Hospitals (Central Coast Local Health District), which will allow both hospitals to enrol patients subject to final site approvals and activation. As of 31 March 2025, Race held cash and cash equivalents of $17.12 million, with more than 70% of spending in the quarter ($1.67m) directed toward R&D and drug manufacturing activities. This prudent cash management enables Race to fund all announced clinical and preclinical programs through CY2026. Other key events during the quarter included the execution of a contract with a Contract Research Organisation to support the clinical development of RC220 and the addition of Race Oncology to the All Ordinaries Index.